Cancer immunotherapy has steadily been gaining momentum over the last decade, due to its proven efficacy as monotherapy in patients with various tumors, including tumors resistant to chemo- or radiotherapy. With an ever-increasing amount of clinical trials reporting significant benefits in long-term overall survival of patients with specific cancers following mono-immunotherapy, the goal has shifted to attaining higher response rates in broader patient populations by employing immuno-oncology (IO) combination approaches. Our research aimed to shed light on the discovery of effective IO combinations and specific tumor indications in which they can attain durable and long-lasting anti-tumor immune responses, by anticipating new developments in the IO field and identifying trends.
This paper describes the results of quantitative and qualitative analysis on phase II, II/III, and III trials that started between the 1stof January, 2014, and 17thof January, 2019. Results werepublishedin theJournal for Clinical Studiesin August 2019.
